Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer
Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.
“This clinical trial is to assess ID-G305 and its ability to activate the immune system in patients with advanced stage melanoma, sarcoma, lung, ovarian, or breast cancer,” said Amit Mahipal, M.D., M.P.H., medical director of Moffitt’s Clinical Research Unit. “Our first patient in this trial is a metastatic sarcoma patient who has undergone two previous surgeries and one chemotherapy regimen.”
ID-G305 is a cancer vaccine that is made up of two parts, a protein called NY-ESO-1 that is found in many different types of cancer, and an agent called GLAASTM developed by Immune Design. GLAASTM activates a type of cell called a dendritic cell that normally searches for pathogens in the body and helps the immune system fight against the infection. Following vaccination, the GLAASTM-activated dendritic cells recognize NY-ESO-1 as a foreign protein and cause the body to produce an immune response. Since NY-ESO-1 is found on tumors, the immune system begins targeting the cancer cells.
“Only 10 to 15 percent of all tumors have NY-ESO-1 protein expression. Therefore, patients for this trial need to be to be screened for NY-ESO-1. The vaccine will likely not work for patients with tumors that do not have detectable levels of the protein,” said Mahipal.
Each component of ID-G305 has been used previously as a single-agent in clinical trials and was well tolerated by patients. This trial will determine the ideal concentration of each agent to use in combination. Common side effects expected include pain, redness, and inflammation at the site of injection.
This is an exciting time for the development of new immunotherapies to fight cancer. Several immunotherapy agents have recently been approved by the Food and Drug Administration, including interleukin-2 for melanoma and renal cell carcinoma, Provenge for prostate cancer and ipilimumab for melanoma.
“New immune therapies are emerging,” explained Mahipal. “If we can have immune therapy actually work it would be great for the patient and reduce side effects associated with traditional chemotherapies.”
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- Malaria research advances immunotherapy in lupus, HIVon November 19, 2019 at 3:03 pm
A new study published on November 19, 2019, in the journal Cell Reports, shows how the body’s immune system responds to malaria, which in turn promises to teach scientists how to design more effective ...
- Brain cancer immunotherapy developed at Roswell Park set for clinical trials next yearon November 19, 2019 at 2:38 pm
A drug called SurVaxM that is designed to treat a form of cancer called glioblastoma, will be used in a large clinical trial in 2020.
- Why Hasn’t Immunotherapy Been Working For Prostate Cancer? Bone Tumors May Be The Answeron November 18, 2019 at 4:00 pm
Researchers from MD Anderson in Texas have uncovered new clues as to why immunotherapy may fail in ... [+] many men with prostate cancer. Immunotherapy drugs called immune checkpoint inhibitors have ...
- Trispecific antibodies offer a third way forward for anticancer immunotherapyon November 18, 2019 at 8:11 am
Immunotherapy approaches seek to boost immune responses against cancer. A single antibody engineered to recognize three targets shows promise, when tested in animals, in improving the ability of T ...
- Immunotherapy Drugs Market : Key Facts and Forecast Predictions Presented Until 2025on November 17, 2019 at 10:21 pm
Nov 18, 2019 (AmericaNewsHour) -- Global Immunotherapy Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025 [104 pages report] This market research report includes a ...
- Findings could identify aggressive breast cancers that will respond to immunotherapyon November 14, 2019 at 9:29 am
The U.S. Food and Drug Administration recently approved a treatment that combines an immunotherapy drug and chemotherapy for triple negative breast cancer, but not all cases of this aggressive form of ...
- Cancer Immunotherapy Market Global Outlook by Size, Share, Trend, Growth, Demand, Industry Analysis, Business Strategies by 2023on November 13, 2019 at 4:25 pm
Amgen Inc., Bristol-Myers Squibb, ELI Lilly and Company, Celgene Corporation, Seattle Genetics, Inc., Spectrum Pharmaceuticals, Inc. Market Research Future has released a new research report on global ...
- Research explains why immunotherapy fails against prostate cancer bone metastaseson November 13, 2019 at 4:00 pm
The discoveries by a team led by Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at MD Anderson, explain why immunotherapy has been largely unsuccessful ...
- Rheumatoid Arthritis Is No Bar to Cancer Immunotherapyon November 13, 2019 at 1:17 pm
Among 22 RA patients treated with checkpoint inhibitors including ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda) -- 12 developed RA exacerbations after starting the ...
- Allergy Immunotherapy Market Improved Prospective CAGR between 2019 and 2026on November 12, 2019 at 10:00 pm
Nov 13, 2019 (Global QYResearch via COMTEX) -- The report on Global Allergy Immunotherapy Market is the latest addition to the huge database of Ameco Research. This research study is segmented on the ...
via Bing News